104
Participants
Start Date
October 31, 2009
Primary Completion Date
December 31, 2014
Study Completion Date
June 30, 2015
sipuleucel-T
Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
NYU Cancer Institute, New York
Mount Sinai School of Medicine Department of Urology, New York
Columbia University Medical Center, New York
Georgetown University Medical Center, Washington D.C.
Hematology Oncology Consultants, Greenbelt
Myron I. Murdock MD LLC, Greenbelt
Urology of Virginia, PLLC, Virginia Beach
GU Oncology Research Program, Durham
Sarah Cannon Research Institute, Nashville
Oncology Hematology Care, Inc., Cincinnati
Indiana University Department of Urology, Indianapolis
Aurora Advanced Healthcare, Inc, Wauwatosa
Oncology Specialists, S.C., Park Ridge
The University of Chicago Medical Center, Chicago
Texas Oncology, PA - Sammons Cancer Center, Dallas
Virginia Mason Medical Center Urology and Renal Transplantation, Seattle
Maine Center for Cancer Medicine, Scarborough
John Theurer Cancer Center at Hackensack, Hackensack
Lead Sponsor
Dendreon
INDUSTRY